Lupin Limited has informed the Exchange regarding a press release dated September 30, 2025, titled "Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension ".
Lupin Limited has informed the Exchange regarding a press release dated September 30, 2025, titled "Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension ".